SURGALIGN HOLDINGS INC (SRGA)
US86882C2044 - Common Stock
SRGA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 192 industry peers in the Health Care Equipment & Supplies industry. SRGA has a bad profitability rating. Also its financial health evaluation is rather negative. SRGA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SRGA has reported negative net income.
In the past year SRGA has reported a negative cash flow from operations.
SRGA had negative earnings in each of the past 5 years.
SRGA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The profitability ratios for SRGA are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRGA's Gross Margin of 47.06% is in line compared to the rest of the industry. SRGA outperforms 43.00% of its industry peers.
In the last couple of years the Gross Margin of SRGA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SRGA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.98%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
SRGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRGA has more shares outstanding
The number of shares outstanding for SRGA has been reduced compared to 5 years ago.
SRGA has a worse debt/assets ratio than last year.
2.2 Solvency
SRGA has an Altman-Z score of -14.39. This is a bad value and indicates that SRGA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -14.39, SRGA is not doing good in the industry: 85.51% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.39 |
ROIC/WACCN/A
WACC5.62%
2.3 Liquidity
A Current Ratio of 2.67 indicates that SRGA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.67, SRGA is doing worse than 60.87% of the companies in the same industry.
SRGA has a Quick Ratio of 2.00. This is a normal value and indicates that SRGA is financially healthy and should not expect problems in meeting its short term obligations.
SRGA has a Quick ratio (2.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.34% over the past year.
The Revenue for SRGA has decreased by -11.04% in the past year. This is quite bad
Measured over the past years, SRGA shows a very negative growth in Revenue. The Revenue has been decreasing by -21.76% on average per year.
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q57.14%
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y-21.76%
Revenue growth Q2Q-18.72%
3.2 Future
SRGA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -26.80% yearly.
SRGA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.28% yearly.
EPS Next Y-58.25%
EPS Next 2Y-26.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-37.13%
Revenue Next 2Y-17.44%
Revenue Next 3Y10.86%
Revenue Next 5Y5.28%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SRGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRGA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SRGA's earnings are expected to decrease with -26.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.8%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SRGA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SURGALIGN HOLDINGS INC
NASDAQ:SRGA (6/30/2023, 7:00:01 PM)
After market: 0.1235 -0.06 (-32.48%)0.1829
-0.09 (-32.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.68M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.06% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.67 | ||
| Quick Ratio | 2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-58.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y